Is GMU the RBL doing the abstract for the DOD abstract? I thought Rutgers RBL was the one doing the research on the really broad spectrum investigation of B, but then I tend to get some facts muddled at times.
Was the ASV abstract kind of a teaser for the DOD abstract since it didn't go that specifically (IMO) into the across the board results for B. Example: anti-inflammatory properties confirmed but just what did this mean and how did they come up with that assertion?
Seems likely GMU should have the full task of exploring B since they started it but maybe it is too big for just one RBL.
Anyway, sure looking to see expanded data and new possibilities for B from the DOD abstract that should be PR'd (again IMO) late in Aug.
Great to know that by Mon we should have the P2 human trial of B for moderate/severe CV19 finished.
Come on Aug, you are welcomed with open arms.
News 
Market Data 
Discover 
